A recent study led by Anna Martling, the ALASCCA trial, provides new evidence that low-dose aspirin (160 mg daily) can reduce recurrence risk in colorectal cancer (CRC) patients with PI3K pathway alterations. Conducted across 33 hospitals in Sweden, Denmark, Finland, and Norway, this randomized, placebo-controlled trial is among the first to assess aspirin’s impact in a targeted CRC population.
After three years of follow-up, the study found:
✔️ A 51% reduction in recurrence risk (HR=0.49, p=0.044) for PIK3CA-mutant CRC
✔️ A 58% reduction in recurrence risk (HR=0.42, p=0.013) for other PI3K-altered CRCs
✔️ Improved disease-free survival, particularly in non-PIK3CA exon 9/20 mutations
These findings suggest that aspirin could serve as an accessible adjuvant therapy for a subset of CRC patients who currently lack targeted treatment options. The safety profile was favorable, with only three severe adverse events.
With this research, Anna Martling and her team contribute to refining precision oncology, offering a cost-effective strategy to reduce recurrence in one-third of CRC patients.
Read the full study here: https://lnkd.in/e_yiRb9U
